The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
Let’s be real: cannabis culture in 2026 looks nothing like it did even a decade…
A first-person review of the hemp-derived THC cocktail base I poured at our Cannabis Cup…
Every paper mill in the world still runs on the continuous-web design a Frenchman patented…
A new AI-assisted sci-fi satire from filmmaker Dan Levy Dagerman and the Space Weed Universe…
Spain has increased penalties for electricity theft linked to indoor cannabis cultivation after Endesa reported…
How a 52-year-old first-time grower turned trial and error into a show-stopping harvest The first…